Accelerating Australia turns leader to transform biomedical expertise
Category: #health  By Dhananjay Punekar  Date: 2018-04-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Accelerating Australia turns leader to transform biomedical expertise

Accelerating Australia, a Biomedical Innovation Group based in Western Australia, has received funds from a consortium of firms for financing its training & medical Biodesign programs. The move is likely to promote partnerships and innovations across myriad pharmaceuticals as well as medical sectors.

For the record, Accelerating Australia came into existence in October in 2017 through an investment of nearly USD 1 million in the form of federal grants. Since then it has received funds from Monash University, Avita Medical, Centre for Entrepreneurial Research and Innovation in Perth, Harry Perkins Institute of Medical Research, St. John of God Healthcare, University of Adelaide, and the University of Sydney.

Experts are of the view that the West Australian group is rapidly emerging as a dominant force across the Australian Biomedical sector through the introduction of innovative therapies and healthcare expertise. A biomedical researcher at Harry Perkins, Kevin Pfleger was quoted stating that the consortium members have put away their differences and business rivalries to financially support Accelerating Australia.

With the new investments, the WA based firm will enter into a collaboration with Spark Co-Lab in the Stanford University located medical innovation project, launched by Spark nearly two years back. Recently, the course has been renamed as Perth Biodesign and is rolled out across the country with its initial launch in Adelaide. The course integrates teams from medical, science, and engineering background for developing new medical equipment to fulfill the unmet medical needs of the patients.  

For the record, Accelerating Australia has registered outstanding results via its training courses that includes brokering multidisciplinary associations, offering commercialization advise, and increasing awareness about biomedical commercial activities.

Participants of the training course have achieved tremendous progress that has made them acquire new technological landmarks. The breakthroughs made by the firms include identification of early phase infections of orthopaedic implants, which is allegedly the focus of Biacor Pty Ltd, spin-out of SPARK Co-Lab Design project.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...